Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973908 | 0.79 | NPC1 (0.47) | KDM4ENAPRTHCAR2BAZ2BADORA3 | |
| Hydrochloric Acid SCHEMBL2554139 | 0.77 | NPC1 (0.46) | KDM4ENAPRTHCAR2BAZ2BADORA3 | |
| SCHEMBL14903392 | 0.76 | — | — | |
| SCHEMBL108950 | 0.75 | KDM4E (0.57) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL29651938 | 0.75 | KDM4E (0.57) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| Hydrochloric Acid SCHEMBL30529579 | 0.73 | KDM4E (0.55) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| Hydrochloric Acid SCHEMBL27902568 | 0.73 | KDM4E (0.55) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| Hydrochloric Acid SCHEMBL29070148 | 0.73 | KDM4E (0.55) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL4904135 | 0.72 | BAZ2B (0.52) | KDM4ENAPRTHCAR2BAZ2BADORA3 | |
| SCHEMBL640866 | 0.72 | KDM4E (0.48) | KDM4ENAPRTHCAR2BAZ2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041393-B1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4041393-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-114867529-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021069567-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| EP-0388528-B1 | Carboximidamide derivatives | KIRIN BREWERY (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5272164-A | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223508-A | Hypotensive agents, vasodilators | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5166347-A | Hypotensive agents, cardiovascular disorders, antiischemic agents and anticoagulants | KIRIN BEER KABUSHIKI KAISHA (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0388528-A2 | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | KDM4E 3823/4885NAPRT 4235/4885HCAR2 132/4885 |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | KDM4E 2583/4885NAPRT 2642/4885HCAR2 96/4885 |
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | PRXL2A, GLRX3, CYP4F3 | KDM4E 2788/4885NAPRT 3878/4885HCAR2 2227/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | KDM4E 3630/4885NAPRT 4150/4885HCAR2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.